The FDA has published more than 200 complete response letters, sent as replies for applications submitted from 2020 to 2024.

Cancer patients without health insurance have not derived the same benefits from the introduction of ICIs as patients with private insurance.

Mass firings and grant terminations have disrupted research and other operations at the National Cancer Institute.

The addition of metformin “was generally well tolerated but did not result in the targeted benefit of a 20% reduction in risk of death in an unselected population,” the researchers wrote.

Olaparib demonstrated activity in a phase 2 trial of patients who had advanced biliary tract cancer with homologous recombination repair (HRR) mutations. Results from this trial were presented at the ...

Cancer Therapy Advisor, a trusted source of medical news and feature content for healthcare providers, offers clinicians insight into the latest research to inform clinical practice and improve ...

Breast cancer patients may have inferior recurrence-free survival after neoadjuvant chemotherapy if they are overweight or obese at diagnosis.

In June, the US Food and Drug Administration approved 7 drugs to treat a range of cancers.

The Trump administration's recent travel and visa restrictions are preventing medical residents from starting their jobs in the US.

The denosumab biosimilars Stoboclo (denosumab-bmwo) and Osenvelt (denosumab-bmwo) are now available in the US.